In Phase C, individuals will get ABBV-744 and oral navitoclax. In Section D, members will get ABBV-744 and ruxolitinib. Individuals will obtain treatment until ailment progression or perhaps the individuals are not able to tolerate the study drugs. - Participant consumed grapefruit or grapefruit solutions within three times previous to https://erasmusk766yju9.blogdomago.com/profile